This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, H. Articles by Zheng, W. Search for Related Content PubMed PubMed Citation Articles by Yu, H. Articles by Zheng, W.

Joint Effect of Insulin-like Growth Factors and Sex Steroids on Breast Cancer Risk¹

Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut 06520 [H. Y.]; Vanderbilt University School of Medicine, Nashville, Tennessee 37232 [X-O. S., Q. D., W. Z.]; Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130 [B. D. L. L.]; and The Shanghai Cancer Institute, Shanghai, People’s Republic of China [Y-T. G., F. J.]

Insulin-like growth factors (IGFs) and estrogens are essential hormones regulating the growth and differentiation of mammary cells. Studies have shown that IGFs and estrogens are strong mitogens for breast cancer cells and that high circulating IGF-I and estrogens are risk factors of breast cancer. Laboratory experiments further indicate that these hormones act synergistically on the pathogenesis of breast cancer. Estrogens increase the effect of IGF-I on breast cancer cells by stimulating the expression of IGF-I and IGF-I receptor; IGFs enhance the action of estrogens by regulating the production of estrogen receptor. Furthermore, the two systems have substantial signal transduction cross-talk. Despite the laboratory indications, there is no epidemiological evidence in support of the joint effect of IGFs and estrogens on breast cancer risk. To test this hypothesis in human populations, we compared plasma levels of IGFs and sex steroid hormones among 300 incident breast cancer patients and 300 age- and menopause-matched control women derived from a large population-based case-control study conducted in Shanghai, China between 1996 and 1998. Fasting morning blood samples were measured for plasma concentrations of IGF-I, IGF-II, IGF-binding protein (IGFBP)-3, estradiol, estrone, estrone sulfate, testosterone, and dehydroepiandrosterone sulfate using commercial immunoassay kits. Levels of these hormones were classified into two groups based on the median levels in the control group and combined between IGFs and steroid hormones. Conditional logistic regression analysis was performed to examine the association of breast cancer risk with the combined variables of sex steroids and IGFs. A synergistic effect on breast cancer risk was suggested for IGF-I or IGFBP-3 with estrone or testosterone among both pre- and postmenopausal women. Compared with premenopausal women with low circulating levels of both IGF-I and estrone, the odds ratios were 1.21 [95% confidence interval (CI), 0.61–2.40] for high estrone, 1.50 (95% CI, 0.77–2.93) for high IGF-I, and 2.30 (95% CI, 1.21–4.37) for both high estrone and high IGF-I. Similar patterns of association were also seen for IGF-I with testosterone as well as for IGFBP-3 with estrone or testosterone, and some of the interactions were statistically significant or borderline significant (P < 0.10). No joint effects were found for IGF-I or IGFBP-3 with estradiol or estrone sulfate. In conclusion, the study suggests a possible synergy between IGF peptide hormone and sex steroid hormones, including both estrogen and androgen, in relation to breast cancer risk.

This article has been cited by other articles:

				A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al. Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209. [Abstract] [Full Text] [PDF]

				M. Hietala, T. Sandberg, A. Borg, H. Olsson, and H. Jernstrom Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women Hum. Reprod., January 1, 2007; 22(1): 83 - 91. [Abstract] [Full Text] [PDF]

				A. Lukanova, P. Toniolo, A. Zeleniuch-Jacquotte, K. Grankvist, M. Wulff, A. A. Arslan, Y. Afanasyeva, R. Johansson, P. Lenner, G. Hallmans, et al. Insulin-like Growth Factor I in Pregnancy and Maternal Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2489 - 2493. [Abstract] [Full Text] [PDF]

				S. A. Adams, C. E. Matthews, J. R. Hebert, C. G. Moore, J. E. Cunningham, X.-O. Shu, J. Fulton, Y. Gao, and W. Zheng Association of physical activity with hormone receptor status: the shanghai breast cancer study. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1170 - 1178. [Abstract] [Full Text] [PDF]

				I. dos Santos Silva, N. Johnson, B. De Stavola, G. Torres-Mejia, O. Fletcher, D. S. Allen, N. E. Allen, T. J. Key, I. S. Fentiman, J. M.P. Holly, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 449 - 455. [Abstract] [Full Text] [PDF]

				M. L. Irwin, A. McTiernan, L. Bernstein, F. D. Gilliland, R. Baumgartner, K. Baumgartner, and R. Ballard-Barbash Relationship of Obesity and Physical Activity with C-Peptide, Leptin, and Insulin-Like Growth Factors in Breast Cancer Survivors Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2881 - 2888. [Abstract] [Full Text] [PDF]

				W. Zheng, W.-H. Chow, G. Yang, F. Jin, N. Rothman, A. Blair, H.-L. Li, W. Wen, B.-T. Ji, Q. Li, et al. The Shanghai Women's Health Study: Rationale, Study Design, and Baseline Characteristics Am. J. Epidemiol., December 1, 2005; 162(11): 1123 - 1131. [Abstract] [Full Text] [PDF]

				C. Mulhall, R. A. Hegele, H. Cao, D. Tritchler, M. Yaffe, and N. F. Boyd Pituitary Growth Hormone and Growth Hormone-Releasing Hormone Receptor Genes and Associations with Mammographic Measures and Serum Growth Hormone Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2648 - 2654. [Abstract] [Full Text] [PDF]

				C. Diorio, M. Pollak, C. Byrne, B. Masse, N. Hebert-Croteau, M. Yaffe, G. Cote, S. Berube, C. Morin, and J. Brisson Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1065 - 1073. [Abstract] [Full Text] [PDF]

				O. Fletcher, L. Gibson, N. Johnson, D. R. Altmann, J. M.P. Holly, A. Ashworth, J. Peto, and I. d. S. Silva Polymorphisms and Circulating Levels in the Insulin-Like Growth Factor System and Risk of Breast Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 2 - 19. [Abstract] [Full Text] [PDF]

				D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF]

				T. G. Nielsen, A. Olsen, J. Christensen, K. Overvad, and A. Tjonneland Dietary Carbohydrate Intake Is Not Associated with the Breast Cancer Incidence Rate Ratio in Postmenopausal Danish Women J. Nutr., January 1, 2005; 135(1): 124 - 128. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, M. Pettinger, M. L. Stefanick, B. V. Howard, Y. Mossavar-Rahmani, and A. McTiernan Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications J. Clin. Oncol., November 15, 2004; 22(22): 4507 - 4513. [Abstract] [Full Text] [PDF]